Skip to content

Sarepta Therapeutics

US · SRPT #2853 by market cap Listed 1970
13.33 -0.84 -5.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:54

Recent news

  • Rating change
    BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Cuts Target Price to $18
    Market Newswire · 2026/10/9
  • Rating change
    Analysts' Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)
    TipRanks · 2026/7/28
  • Barclays Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $20
    Market Newswire · 2026/11/9
  • Rating change
    J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Raises Target Price to $23
    Market Newswire · 2026/9/2
  • Company notice
    Tradr 2X Long SRPT Daily ETF: Tradr 2X Long SRPT Daily ETF - Liquidation/Cash Settlement/Acceleration of Expirations Option Symbol: SRPU
    OCC · 2026/6/24
  • Citi Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $13
    Market Newswire · 2026/11/9
  • Rating change
    J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Announces Target Price $20
    Market Newswire · 2026/9/30
  • Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $20
    Market Newswire · 2026/11/13
  • Rating change
    H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5
    Market Newswire · 2026/10/30
  • Company notice
    Tradr 2X Long SRPT Daily ETF | 497: Periodic update to fund prospectus
    SEC · 2026/5/21
  • Rating change
    Wedbush Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/10/26
  • Rating change
    Needham Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating
    Market Newswire · 2026/9/28
  • A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $5 to $38
    Market Newswire · 2026/11/7
  • Rating change
    J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)
    TipRanks · 2026/9/2
  • Rating change
    Evercore Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $19
    Market Newswire · 2026/8/10
  • Rating change
    William Blair Initiates Sarepta Therapeutics(SRPT.US) With Hold Rating
    Market Newswire · 2026/9/29
  • Company notice
    Tradr 2X Long SRPT Daily ETF: Tradr 2X Long SRPT Daily ETF - Anticipated Liquidation/Anticipated Cash Settlement Option Symbol: SRPU
    OCC · 2026/6/4
  • Deutsche Bank Upgrades Sarepta Therapeutics(SRPT.US) to Hold Rating, Raises Target Price to $18
    Market Newswire · 2026/11/10
  • Rating change
    J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating
    Market Newswire · 2026/9/15
  • Rating change
    BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $18
    Market Newswire · 2026/11/2
  • Rating change
    A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $5 to $38
    Market Newswire · 2026/8/7
  • Rating change
    Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $31
    Market Newswire · 2026/7/10
  • Rating change
    Morgan Stanley Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $25
    Market Newswire · 2026/7/27
  • Rating change
    Citi Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $13
    Market Newswire · 2026/9/28
  • Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $20
    Market Newswire · 2026/10/19

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:54:28 · For reference only, not investment advice and not tailored to your situation.

Sarepta Therapeutics discussion 0 comments

Add a comment